Beactica Announces Drug Discovery Agreement With Cubist Pharmaceuticals

UPPSALA, Sweden, May 25 /PRNewswire/ -- Beactica AB, the Swedish
fragment-based drug discovery company, today announced that it has entered
into an agreement with Cubist Pharmaceuticals, Inc. (Lexington, MA; NASDAQ:
CBST). Under the agreement, Beactica will use its Sprint(TM) surface plasmon
resonance (SPR)-integrated drug discovery platform to target multi-component
proteins from pathogenic bacteria of interest to Cubist. Financial terms of
the agreement were not disclosed.
"We are pleased to be working with Cubist in their quest to develop
next-generation anti-bacterials" said Beactica CEO, Dr Per Kallblad. "Cubist
has excellent strengths in the area and it is a source of pride to have been
selected to help progress one of their discovery programmes."
Cubist becomes the fifth life-science company to enter an agreement with
Beactica in the past eighteen months.
About Beactica
Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the biophysical interaction of
molecules in order to generate novel therapeutics. Beactica's Sprint(TM) drug
discovery platform efficiently integrates surface plasmon resonance (SPR) to
accelerate the identification of optimal starting points and development
routes for lead discovery. The company was spun out of Uppsala University in
August 2006. As well as building collaborations with external companies,
Beactica is progressing its own drug discovery programmes of small molecule
therapeutics. For more information about Beactica, please visit
http://www.beactica.com.
SOURCE Beactica AB

For further information, please contact Dr Per Kallblad, CEO Beactica,
+46(0)18-56-08-80.